Improving Inflammatory Bowel Disease with Probiotics and Medication
Author Information
Author(s): Ma Weiwei, Wu Yanan, Lin Xinyue, Yang Liping, Huang Lili
Primary Institution: College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China
Hypothesis
Can Bifidobacterium animalis subsp. lactis XLTG11 combined with mesalazine improve the treatment of inflammatory bowel disease?
Conclusion
The combination of Bifidobacterium animalis subsp. lactis XLTG11 and mesalazine significantly improved symptoms of inflammatory bowel disease in mice.
Supporting Evidence
- The XLTG11+5-ASA group showed superior recovery compared to the XLTG11-only and 5-ASA-only groups.
- The combination treatment significantly reduced myeloperoxidase activity and intestinal permeability.
- The treatment increased levels of beneficial short-chain fatty acids and improved gut microbiota composition.
Takeaway
This study found that a special probiotic combined with a common medicine helped mice with a gut disease feel better.
Methodology
Sixty mice were divided into five groups and treated with different combinations of Bifidobacterium animalis subsp. lactis XLTG11 and mesalazine, followed by assessments of body weight, intestinal permeability, cytokine levels, and microbiota composition.
Potential Biases
Potential funding bias from the National Natural Science Foundation of China and other grants.
Limitations
The study was conducted on mice, and results may not directly translate to humans.
Participant Demographics
BALB/c mice, 60 total, housed in controlled conditions.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website